Q3 2017 13F Holders as of 9/30/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.3M
-
Number of holders
-
30
-
Total 13F shares, excl. options
-
9.32M
-
Shares change
-
-603K
-
Total reported value, excl. options
-
$27.5M
-
Value change
-
-$1.98M
-
Number of buys
-
8
-
Number of sells
-
-14
-
Price
-
$2.95
Significant Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q3 2017
40 filings reported holding XENE - Xenon Pharmaceuticals Inc. - Common Stock as of Q3 2017.
Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 30 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.32M shares
of 77.3M outstanding shares and own 12.05% of the company stock.
Largest 10 shareholders include BVF INC/IL (3.59M shares), Capital World Investors (1.43M shares), ORBIMED ADVISORS LLC (635K shares), Alyeska Investment Group, L.P. (449K shares), DAFNA Capital Management LLC (378K shares), Invesco Private Capital, Inc. (376K shares), Tekla Capital Management LLC (350K shares), Point72 Asset Management, L.P. (310K shares), SABBY MANAGEMENT, LLC (308K shares), and Schonfeld Strategic Advisors LLC (275K shares).
This table shows the top 30 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.